Overview

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Eligibility

Inclusion Criteria:

• Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
• Intention-to-initiate first-line tumour therapy for this advanced disease.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

Exclusion Criteria:

• Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.